Tag: Onpattro

NICE Onpattro approval puts Alnylam back in hATTR running

by Anna Smith | Jul 9, 2019 | News | 0

NICE issued the drug a preliminary ‘no’, back in December 2018.

NICE rejects NHS funding for Tegsedi, Onpattro

by Selina McKee | Dec 12, 2018 | News | 0

The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).

Alnylam’s RNA therapy Onpattro bags EU nod

by Selina McKee | Aug 31, 2018 | News | 0

Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.

Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis

by Selina McKee | Aug 13, 2018 | News | 0

The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.